Novo Nordisk A/S filed a lawsuit against Eli Lilly & Co. on Tuesday, July 21, 2026 [1], alleging false advertising for weight-loss drugs.
The legal battle highlights the intense competition between the two pharmaceutical giants as they fight for dominance in the lucrative obesity medication market. Because these drugs are prescribed by physicians and sought by millions of patients, the accuracy of efficacy data is critical to market share.
Novo Nordisk alleges that Eli Lilly's U.S. advertising for Zepbound and Mounjaro uses outdated trial data and misrepresents the effectiveness of Novo's own products, Wegovy and Ozempic [2]. The company argues that these misleading claims distort how patients and prescribers perceive the relative efficacy of the different treatments [3].
"Lilly’s TV and social‑media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than our injections," said John Kuckelman, Novo Nordisk Group General Counsel and Senior Vice President [4].
Novo Nordisk claims that by using obsolete results, Eli Lilly has gained an unfair marketing advantage in the U.S. federal court district where the filing occurred [2, 5]. The lawsuit seeks to address how the rival company presents its clinical success compared to the results seen in Novo Nordisk's product line [3].
Eli Lilly has denied the allegations. "Our ads are truthful and transparent and we will defend vigorously," a company spokesperson said in a statement to Bloomberg [4].
The dispute centers on whether the advertising campaigns provide a fair and current representation of medical trial outcomes, or if they intentionally omit newer data to favor Zepbound and Mounjaro over the competition [2, 6].
“Lilly’s TV and social‑media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than our injections.”
This litigation underscores a shift in the GLP-1 agonist market from a race of discovery to a race of perception. As both companies have established effective products, the battle has moved to the marketing of incremental efficacy gains. A court ruling on what constitutes 'outdated' data could set a precedent for how pharmaceutical companies must update their advertising in real-time as new clinical trials emerge.
